Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Dermatologic 3Thoracic 2Sarcoma 2Breast 2Plasma cell 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 5Melanoma 3Breast Neoplasms 3Sarcoma 2Head and Neck Neoplasms 2Urinary Bladder Neoplasms 1Testicular Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma 1Kidney Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

pembrolizumab 13Nivolumab 6Docetaxel 6cemiplimab 5avelumab 5atezolizumab 5Trastuzumab 5Carboplatin 4durvalumab 3Polymerase Chain Reaction 3Magnetic Resonance Spectroscopy 3Gene Expression Profiling 3Gemcitabine 3Fluorouracil 3Cisplatin 3Biopsy 3zimberelimab 2utomilumab 2ulixertinib 2tisotumab vedotin 2pertuzumab 2palbociclib 2belinostat 2amminedichloro(2-methylpyridine)platinum(II) 2Tetrahydrouridine 2Radiotherapy 2Radiosurgery 2Oxaliplatin 2Nicotine 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × poly ICLC × Head & Neck × Clear all
NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

Phase 1/2 Completed
58 enrolled 24 charts
BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡